XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 39.53

Change

-0.78 (-1.94)%

Market Cap

N/A

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-4.09 (-3.01%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.78 (-2.77%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-1.10 (-1.07%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.74 (-0.89%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.44 (-2.23%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.84 (-0.85%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.70 (-2.48%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.19%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.44 (-2.59%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.32 (-1.78%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.69 % 0.00 %

-0.08 (-0.29%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.05% 33% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.05% 33% F 19% F
Trailing 12 Months  
Capital Gain -3.89% 67% D+ 32% F
Dividend Return 1.23% 94% A 26% F
Total Return -2.66% 71% C- 27% F
Trailing 5 Years  
Capital Gain -6.22% 24% F 26% F
Dividend Return 5.92% 68% D+ 12% F
Total Return -0.29% 33% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -3.79% 33% F 19% F
Dividend Return -2.97% 33% F 13% F
Total Return 0.82% 68% D+ 20% F
Risk Return Profile  
Volatility (Standard Deviation) 12.99% 67% D+ 70% C-
Risk Adjusted Return -22.85% 24% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.